Francisella tularensis is an intracellular pathogen and is able to invade several different cell types, in particular macrophages, most commonly through phagocytosis. A flow cytometric assay was developed to measure bacterial uptake, using a fluorescein isothiocyanate-labelled anti-F. tularensis lipopolysaccharide antibody in conjunction with antibodies to cell surface markers, in order to determine the specific cell phenotypes that were positive for the bacteria. Several phagocytic inhibitors were evaluated in macrophage cell lines and a lung homogenate assay to determine whether the uptake of F. tularensis strain LVS could be altered. Our data show that cytochalasin B, LY294002, wortmannin, nocodazole, MG132 and XVA143 inhibitors reduced LVS uptake by 4 50% in these assays without having significant cytotoxic effects. Furthermore, a reduction in the inflammatory cytokines monocyte chemoattractant protein-1, interleukin-6 and tumour necrosis factor-a was found in the supernatant of lung tissue infected with LVS when the inhibitory compounds were present. Similarly, there was an alteration in bacterial uptake and a reduction in the inflammatory cytokine response following the administration of wortmannin to LVS-infected mice. Although wortmannin treatment alone did not correlate with the enhanced survival of LVS-infected mice, these inhibitors may have utility in combination therapeutic approaches or against other intracellular pathogens that use phagocytic mechanisms to enter their optimal niche.
Introduction
Francisella tularensis is a gram-negative bacterium first discovered by Edward Francis in Tulare County in 1911 (Olsufjev & Meshcheryakova, 1982) . Francisella tularensis is subdivided into biovars, in particular tularensis (also known as type A strains), holarctica (also known as type B strains) and mediasiatica, all of which vary in their degree of virulence (Johansson et al., 2004; Sjostedt, 2007) . Francisella tularensis infection causes a flu-like disease called tularaemia, which can become fatal if left untreated (Evans et al., 1985) . The infection route, dose and type can alter the severity of the disease (Ellis et al., 2002) .
Interest in studying F. tularensis has increased in recent years, not only due to the designation of the pathogen as a potential biological warfare agent (Titball et al., 2007) , but also as a bacterium that can be researched to understand the mechanisms of intracellular pathogens (Oyston, 2008) . As a potential biowarfare agent, there is a need for effective medical countermeasures for F. tularensis infection. Tularaemia is usually treated effectively with the antibiotic ciprofloxacin, although it is known that relapses can occur, both in experimental studies with inhalational tularaemia (Russell et al., 1998; Piercy et al., 2005; Steward et al., 2006) and in clinical cases (Perez-Castrillon et al., 2001; Meric et al., 2008) . In the 1950s, an attenuated strain of F. tularensis ssp. holarctica was developed and this has been used as a vaccine in humans, proving partially effective in providing protection against virulent F. tularensis (Tigertt, 1962; Eigelsbach et al., 1967) . This strain is now called the live vaccine strain (LVS). However, the licence for LVS use in humans has recently been revoked due to the unknown nature of the attenuation and concerns of reversion to full virulence (Oyston, 2009) . Nonetheless, LVS is pathogenic in mice and the course of infection that develops resembles that seen in tularaemia in humans. Therefore, LVS infection in the murine model is a useful tool with which to study human infection with F. tularensis and other intracellular bacteria.
It is well documented that F. tularensis can invade several different host cell types (Buddingh & Womack, 1941; Shepard, 1959; Anthony et al., 1991; Ben Nasr et al., 2006) and the macrophage is considered its optimal niche (Fortier et al., 1994) . The bacterium is able to replicate within the macrophage cytosol, evading killing by disrupting phagosome-lysosome fusion (Rosenberg & Allen, 2006; Haas, 2007) . The ability of F. tularensis to reside within this niche prevents the generation of an adequate immune response to eradicate the infection (Oyston, 2008) .
The host response to infection generally involves receptors present on the surface of host phagocytic cells, which are capable of recognizing a variety of microbial components. In recent years, studies aimed at understanding the pathogenesis of intracellular bacteria have utilized various approaches to inhibit phagocytosis of host cells (Rosenshine et al., 1992; Lieberman & Higgins, 2009) . Of the wide range of receptors, the mannose receptor (MR), complement receptor 3 (CR3) and class A scavenger receptors all play a role in the uptake of F. tularensis into host cells via phagocytosis (Pierini, 2006; Schulert & Allen, 2006) .
Although phagocytic cells, such as macrophages, are generally considered essential to the host innate immune response to infection, the ability of pathogens such as F. tularensis to survive intracellularly has led to the hypothesis that a reduction of bacterial uptake into host cells may improve the eradication of infection through enhancing the exposure of the pathogen to humoral defences. Additionally, such prevention of uptake of F. tularensis into phagocytes may lead to a reduction in the host inflammatory response, which may be damaging if uncontrolled. This study has aimed to evaluate this hypothesis using F. tularensis as a model intracellular pathogen. Specifically, a number of inhibitors that reduce bacterial uptake have been studied for their effect on F. tularensis pathogenesis and the cellular response to infection using a variety of infection models.
Materials and methods

Bacteria, cells and reagents
Francisella tularensis strain LVS was derived from an original NDBR101, Lot 4 vaccine ampoule produced during the 1960s, which had been stored at À 20 1C in the culture collection at the Defence Science and Technology Laboratory (DSTL). Bacteria were cultured overnight at 37 1C on supplemented blood cysteine glucose agar (BCGA) and harvested into Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Paisley, UK) containing 10% foetal calf serum (FCS), 2 mM L-glutamine (culture media). The murine macrophage cell line J774A.1 and the murine alveolar-type macrophage cell line, MH-S (ECCAC, Salisbury, UK), were cultivated at 37 1C with 5% CO 2 , 95% humidity in culture media until confluent. Nocodazole, MG132 (Z-Leu-Leu-Leu-al), wortmannin (from Penicillium funiculosum, Z98%), cytochalasin B (from Drechslera dematioidea), genistein (synthetic, Z98%) and LY-294,002 hydrochloride were obtained from Sigma-Aldrich Co. Ltd (Poole, UK). XVA143 was provided by Dr Nader Fotouhi (Roche, Nutley, NJ). Each of these inhibitor compounds was dissolved in phosphate-buffered saline (PBS) using small amounts (o 10%) of dimethyl sulphoxide as required. Unless otherwise stated, all other reagents were obtained from Sigma-Aldrich Co. Ltd.
Cytotoxicity assays
The cytotoxicity of the inhibitor compounds was assessed through the measurement of cell death using the LDH PLUS assay (Roche Diagnostics Ltd, Lewes, UK). This quantifies the cytoplasmic enzyme lactate dehydrogenase (LDH) that is released into the culture supernatant following damage to the cytoplasmic membrane and is proportional to cell death. Briefly, MH-S cells were seeded at approximately 5 Â 10 5 cells per well in a 96-well plate and incubated at 37 1C, 5% CO 2 , 95% humidity for 24 h. Inhibitors were added and incubated for a further 3 h. Subsequently, the cell-free culture supernatant was collected and LDH release was analysed colorimetrically via an ELISA plate reader at OD 450 nm . Positive control samples were generated by lysing the cells with a cell lysis solution. All tests were performed in triplicate, with the cytotoxicity of inhibitors calculated as a percentage of the control (assuming 100% cytotoxicity).
Measurement of LVS uptake in macrophage cells
A 24-well plate seeded with approximately 1 Â 10 6 cells per well of J774A.1 or MH-S cells was incubated overnight at 37 1C, 5% CO 2 , 95% humidity. Cells were infected with approximately 5 Â 10 7 CFU of LVS, alone or with an inhibitor, and incubated for a further 2 h. Subsequently, cells were washed three times in FACS buffer [0.1% bovine serum albumin (BSA), 0.05% sodium azide in PBS], and then permeabilized for 45 min (100 mL PBS, 1% BSA, 2 mL 0.5 M EDTA and 0.2 g saponin). Nonspecific antibody binding was prevented via incubation with 0.25 mg anti-Fc-g receptor I/ III (CD16/CD32) antibody (BD Biosciences, Mountain View, CA) for 45 min at 4 1C. Cells were then stained with CD45 (APC-Cy7) (BD Biosciences) and a fluorescein isothiocyanate (FITC)-labelled anti-F. tularensis lipopolysaccharide antibody (Detection Department, DSTL, Porton Down) for an additional 30 min at 4 1C. Appropriate isotype controls were added to duplicate samples. Cell samples were vigorously washed, to remove any extracellularly bound LVS organisms and resuspended in equal quantities of FACS buffer and FACS fix (2% formaldehyde in PBS), and then analysed on FACSCanto II (Becton Dickinson) using FACS DIVA software (BD Biosciences). A minimum of 10 000 events was recorded for each sample, with percentage changes generated in reference from a positive control sample. The percentage of cells positive for intracellular LVS was therefore determined.
Additionally, the measurement of intracellular LVS was determined by the enumeration of bacteria on agar. LVS, alone or with an inhibitor, was added to MH-S cells as described above. Plates were incubated at 37 1C, 5% CO 2 for 2 h. To remove extracellular bacteria, 20 mg gentamicin was added to the cells for a further 1 h. After the removal of the supernatant, the remaining cells were lysed using 300 mL of distilled water. The lysate was serially diluted in PBS and viable bacteria were enumerated on supplemented BCGA plates.
Confocal imagery
Cell samples assessed by flow cytometry were also analysed using confocal microscopy. Cells were visualized using an Olympus IX70 confocal laser-scanning microscope. An argon laser was used to excite the CD45 (APC-Cy7) and the FITC-labelled anti-F. tularensis lipopolysaccharide antibody. Images were taken using the onboard camera and any image editing was completed using FLUOVIEW version 5.0 software (Olympus Corporation).
Measurement of LVS uptake in lung cells
Lungs were removed from naïve Balb/c mice and placed into 2 mL of culture media, and then macerated and incubated for 45 min at 37 1C in DMEM containing 10% FCS, 2 mM L-glutamine, 4 mg mL À1 liberase and 10 mg mL À1 DNase.
Following incubation, a single-cell suspension was generated by passing lung tissue through a 40-mm cell strainer (BD Biosciences). The cells were washed once in culture media and then resuspended in 2 mL of RBC lysis buffer (Ebioscience) and incubated for 5 min at 37 1C. Cells were washed twice in culture media and resuspended in 1 mL of culture media. The cell concentration was determined using a Cellometer TM Auto T4 automated cell counter (Peqlab, UK). To perform the assay, 200 mL of approximately 1 Â 10 6 cells mL À1 were added to a 24-well plate with LVS, alone or with an inhibitor. As described for the macrophage uptake assay, cells were incubated and subsequently washed and permeabilized, and nonspecific antibody binding was prevented. 
In vivo evaluation of wortmannin treatment
Groups of six Balb/c mice, housed in a flexible containment isolator, were challenged via the intranasal route with approximately 2 Â 10 4 CFU of LVS. All intranasal dosing was performed following anaesthesia by inhalation of 2-bromo-2-chloro-1,1,1-trifluoroethane (halothane). At the time of infection and at 24, 48 and 72 h postinfection, mice were administered with 50 mg of wortmannin or PBS via the intraperitoneal or the intranasal route. Mice were culled at 96-h postinfection and exsanguinated using a cardiac puncture following terminal anaesthesia with halothane. The lungs, spleen and liver were also harvested and processed within 1 h postmortem.
In a further experiment, groups of 10 Balb/c mice were challenged via the intranasal route with approximately 1.6 Â 10 5 CFU of LVS and administered with 50 mg of wortmannin or PBS via the intranasal or the intraperitoneal route once daily, starting at the time of infection. Mice were weighed and monitored for clinical signs (weight, mobility and vision) twice daily and were culled upon reaching a terminal endpoint.
Sample preparation
Blood samples were diluted 1 : 10 in PBS. The lungs, liver and spleen samples were homogenized in 2 mL of PBS through 40-mm cell sieves (BD Biosciences) using the plunger of a 2-mL syringe. Subsequently, 100-mL aliquots of the cell suspension or blood samples were plated onto BCGA plates for the enumeration of bacterial loads. Further 200-mL aliquots were used for cell infiltration/bacterial uptake analysis via flow cytometry. Supernatants from these samples were removed for cytokine analysis.
Statistical analyses
All graphs and analyses were produced using GRAPHPAD PRISM V4.0 and V5.0 (San Diego, CA). Data generated in this included bacterial data, absolute cells counts and proportional cell counts. All data were log 10 , with the exception of the bacterial count data from the in vitro experiment, transformed for statistical analysis. Data were assessed for use in parametric analyses using the D'Agostino and Pearson's omnibus normality test. Parametric two-way ANOVAs with Bonferroni's comparisons were performed to analyse the majority of the data. Because of deviation from the normal distribution, bacterial colonization of mice was compared using Kruskal-Wallace tests and Dunn's multiple comparisons. Bacterial colonization of in vitro cell lines was calculated using a one-way ANOVA with Bonferroni's comparisons.
Results
Identification of inhibitors of F. tularensis uptake into macrophages
The use of phagocytic inhibitors to disrupt uptake of bacteria into cells is well documented and several studies have demonstrated the inhibition of F. tularensis uptake. In order to determine inhibitors of F. tularensis phagocytosis, selected inhibitor compounds (shown in Table 1 ) were evaluated in vitro for their ability to inhibit uptake of LVS into J774A.1 cells using flow cytometric analysis of FITClabelled bacteria (Fig. 1a-e) . To validate the methodology used, prepared cells were also visualized using confocal microscopy. Figure 1f shows J774A.1 cells stained red with the anti-CD45 marker and internalized LVS stained green. In no instance did the confocal imagery show any surfacebound LVS. However, variations in the exact number of bacteria within the cells did occur, limiting the flow cytometric method to identifying only infected cells. Preliminary screening of the compounds was performed using the compounds at concentrations derived from previously published studies and at concentrations 10-fold higher or lower (data not shown). Of these concentrations, the optimum concentration was used to determine the inhibition of LVS uptake into the cells. The percentage inhibition was determined by calculating the difference between LVS-infected cells in the absence or presence of an inhibitor compound. The compounds that showed o 20% inhibition in our assay (mannan, fucoidan, poly I, staurosporine and PI-PLC) were removed from further analysis. Subsequently, seven compounds were evaluated for the inhibition of LVS uptake into MH-S cells using the same concentrations of compound as in the J774A.1 cell infection assay. The MH-S alveolar-type cells may be more representative of macrophages present in the lung that phagocytose F. tularensis following inhalational infection. Overall, the inhibition of LVS uptake afforded by the inhibitors ranged from 15.7% to 70.2% and there was no statistically significant difference between inhibitions in the two different cell types used (Fig. 1g) .
Optimization of inhibition of LVS uptake in vitro
Our preliminary data evaluating the inhibition of LVS uptake into cells suggested that three of the seven compounds (nocodazole, genistein and cytochalasin B) may be cytotoxic at the concentrations used to obtain inhibition (data not shown). Therefore, the remaining four compounds (LY294002, wortmannin, MG132 and XVA143) were selected for the optimization of inhibition in MH-S cells. These compounds were evaluated for their ability to inhibit LVS uptake at a wide range of concentrations using the flow cytometric assay. Furthermore, the cytotoxicity of the inhibitor compounds at each concentration was measured using an LDH release assay in order to determine the optimal concentration to achieve the inhibition of LVS uptake with little or no cytotoxic effects. All four compounds showed a saturation effect, with higher concentrations of compounds causing no significant increase in the inhibition of LVS uptake (Fig. 2a-d ). At the concentrations tested, only LY294002 became considerably cytotoxic (20% toxicity at a concentration of 400 mM; Fig. 2a) . However, high levels of inhibition of LVS uptake were achieved using only 50 mM LY294002 (Fig. 2e) , which was not measurably cytotoxic in the LDH release assay. To demonstrate that the flow cytometry assay accurately measured bacterial uptake into cells, LVS inhibition was also measured by the enumeration of bacteria on agar. MH-S cells infected with LVS in the absence of an inhibitor compound contained approximately 6 Â 10 6 CFU, whereas the intracellular content was significantly reduced to approximately 2 Â 10 6 CFU following the addition of the four different compounds ( Fig. 2f ; P o 0.01 in each case).
Inhibition of LVS uptake into lung cells
A flow cytometry assay described by Hall et al. (2008) was adapted to evaluate the inhibition of LVS uptake into mouse lung cells (Fig. 3) . Live cells derived from homogenized naïve mouse lungs were identified via their forward (FSC)/ side scatter (SSC) profile and previous analysis of 7AAD (Fig. 3a) , which binds DNA, and hence dead cells are positive for this marker. Individual cells were analysed by excluding those cells that did not fit within a linear positive correlation when comparing FSC-H against FSC-A (Fig. 3b ). Leucocytes were characterized by their expression of CD45 (Fig. 3c) , with all further cell typing characterized after positive expression of this marker. Neutrophils were ) was cultured with LVS in the presence or absence of an inhibitor (2 h at 37 1C). Cell populations, as measured by flow cytometry, were determined by gating on live cells determined by FSC and SSC (a) and previous analysis with 7AAD, followed by doublet cell exclusion (b). Leucocytes were determined by their expression of CD45 (APC-Cy7) (c). Neutrophils were analysed and excluded from downstream measurements via their expression of Ly6G (PE) (d). Alveolar macrophages were determined via their high expression of F4/80 (APC), CD11b (PerCP cy5.5) and CD11c (PE-Cy7). Pulmonary macrophages were characterized by their F4/80 (Fig. 3d) . The F4/80 marker was used to determine macrophage phenotypes (Fig. 3e) 
CD11c
À cells considered as pulmonary macrophages (Fig.   3f ). Dendrocytes and monocytes were identified via their lack of expression of F4/80 and differential expression of CD11c and CD11b (Fig. 3g) . A FITC-labelled anti-F. tularensis lipopolysaccharide antibody was used in conjunction with the cell-specific surface markers to identify LVS-infected cell types. Figure 3h shows representative data from cells that were uninfected or infected with LVS in the absence or presence of the inhibitor wortmannin. The cells from inhibitor-treated samples show a reduction in FITC expression when compared with untreated infected samples. All of the individually characterized cell types were evaluated for LVS uptake following the addition of the four compounds, LY294002, wortmannin, XVA143 and MG132. The measurement of FITC expression enabled the calculation of the percentage of each cell type that was infected with LVS (Fig. 4) . A significant level of uptake of bacteria was visualized in both alveolar macrophage and pulmonary macrophage populations compared with uninfected controls (P o 0.001). Furthermore, a reduction of LVS uptake was afforded by the XVA143 inhibitor in the pulmonary macrophage population (P o 0.05). In addition, all four inhibitors caused a significant reduction in bacterial uptake in the alveolar macrophage population (LY294002, P o 0.05; wortmannin, P o 0.05; MG132, P o 0.001; XVA143 P o 0.05). Uninfected organ homogenates treated only with an inhibitor were included as negative controls, but the inhibitors induced no measurable cytokine production nor had any measurable effect on the cells (data not shown). In comparison, no significant reduction in bacterial uptake was observed in the other cell populations, most likely due to their smaller population sizes (as observed by FACS; data not shown) coupled with a generally low LVS uptake in these cell types.
Reduced inflammatory response following the inhibition of LVS uptake into lung cells
A strategy to prevent LVS uptake into host cells, thereby depriving the bacterium of its replicative niche, may have therapeutic benefit for the outcome of infection. In order to indicate the effect that these four inhibitors may have on the immune response induced by LVS, the lung homogenate infection assay was used. Inhibitor compounds were added to the cell homogenate at the same time as LVS infection. Following infection and the addition of the inhibitors, cell supernatants removed at 24-h postinfection were analysed for cytokine content (Fig. 5) . Lung cells infected with LVS secreted significantly increased amounts of IL-6 and TNF-a when compared with uninfected cells (P o 0.05 and P o 0.001, respectively). In comparison, the production of IL-10 and IL-12p70 was not altered following infection with LVS. Interestingly, the inhibitor compounds caused a reduction in the secretion of several inflammatory cytokines. MG132 caused reductions in the secreted levels of IL-6, MCP-1 and TNF-a when compared with noninhibited control cells (P o 0.001, P o 0.05 and P o 0.001, respectively). LY294002 and wortmannin also caused a reduction in the level of IL-6 produced (P 4 0.001 for both), although there was no significant reduction in IL-6 levels in XVA143-treated cells. In comparison, XVA143 caused a reduction in the secreted levels of MCP-1 when compared with noninhibited control cells (P o 0.05), whereas LY294002 and 
In vivo assessment of wortmannin
The in vitro cell infection data and ex vivo lung infection data generated in this study suggested that LVS uptake into phagocytic cells and the associated inflammatory response could be reduced following the addition of phagocytic inhibitors, not only before infection but also at the time of infection. In order to progress to further experiments in vivo, preliminary experiments were performed on all four compounds to determine a tolerated dose and route of administration. The inhibitors have all been administered in other studies via the intraperitoneal route (Hu et al., 2000; Letoha et al., 2005; Hajishengallis et al., 2007; Teranishi et al., 2009) . However, for the evaluation of therapeutic efficacy against inhalational LVS infection, administration by the intranasal route was considered more appropriate. In this study, all four compounds were tolerated by naïve mice when administered by either the intranasal or the intraperitoneal route, at concentrations determined by our preliminary data and the published studies. Furthermore, subsequent ex vivo infection assays with homogenates prepared from lung and spleen tissue removed from the compound-treated mice indicated a reduced inflammatory cytokine response when compared with infection of tissue homogenates from nontreated mice (data not shown). On the basis of the preliminary data, wortmannin was chosen for a more detailed evaluation due to its promising effect on cytokine responses in the both the spleen and the lungs. Mice were infected with LVS via the intranasal route and were treated daily with wortmannin via the intranasal or the intraperitoneal route. Mice were then culled at 96-h postinfection. Bacterial colonization and cytokine response were determined in the lung, liver, spleen and blood. In addition to these parameters, the concentration of professional phagocytes (macrophages, monocytes, dendrocytes and neutrophils) and the bacterial uptake into these cells were also measured. Significant reductions in bacterial growth were only observed in the spleen following the intraperitoneal treatment of wortmannin (P o 0.05; Fig.  6c ). However, there was a suggestion of intranasal and intraperitoneal treatment with wortmannin affecting lung infection by LVS, although this was not statistically significant in this study (Fig. 6a) . Interestingly, the bacterial load in the blood of animals treated with wortmannin was increased when compared with nontreated controls (Fig. 6b) . Overall, the impact that phagocyte numbers had on LVS uptake was not significant. However, treatment with wortmannin by both the intraperitoneal and the intranasal route correlated with a reduction in the concentration of total phagocytes within the lung (P o 0.001, data not shown).
Despite the lack of significant changes in bacterial uptake following wortmannin treatment in the lung and liver, all organs showed significant reductions in inflammatory cytokines (Fig. 7) . In the lung, wortmannin, administered by either route of administration, caused significant reductions in secreted IL-6, MCP-1, TNF-a and IFN-g (P o 0.001; Fig.  7a-e) . Additionally, wortmannin treatment caused a significant reduction in the cytokine levels of IL-10 and IL-12p70 in the lung when administered via the intranasal route (P o 0.001), but not the intraperitoneal route (Fig. 7f) . Lower levels of cytokine secretions were detected in the liver, spleen and blood, and wortmannin had no significant effect on cytokine secretions in these organs, except in the spleen, where IFN-g was reduced when compared with untreated controls (P o 0.001) (Fig. 7d) .
The in vivo data generated with wortmannin confirmed our data generated in vitro and with ex vivo lung homogenates, i.e. the inhibitor caused an altered bacterial uptake profile and a reduced inflammatory cytokine response. To Published by Blackwell Publishing Ltd determine whether the approach of phagocytic inhibition of LVS could alone provide a protective effect against infection, wortmannin treatment was assessed in a lethal mouse model of LVS infection. Mice were infected via the intranasal route with LVS and treated with wortmannin daily via the intranasal or the intraperitoneal route. Mice were monitored twice daily for changes in clinical signs, weight loss and survival. Unfortunately, whether delivered via the intraperitoneal or the intranasal route, there was no significant change in the survival time, clinical scores or weight loss in wortmannin-treated mice when compared with untreated LVS-infected controls (data not shown).
Discussion
Francisella tularensis replicates rapidly inside host cells and can be lethal by infection with a single organism (Bell et al., 1955) . The uptake of bacteria into host cells is controlled by phagocytosis. Host cell receptors such as scavenger receptors and integrins bind with bacterial cell ligands, causing cytoskeletal reorganization and uptake of the pathogen (Stuart & Ezekowitz, 2005) . In this study, we sought to identify whether a number of candidate phagocytic inhibitors could affect uptake of F. tularensis into different cell types and determine the effect on the host inflammatory response and subsequent survival. The phosphatidylinositol-3-kinase inhibitors LY294002 and wortmannin, the CR3 blocking compound XVA143 and the proteasome inhibitor MG132 were found to significantly reduce bacterial uptake into murine cells. The phagocytic inhibitor compounds reduced bacterial uptake in an ex vivo lung infection model and in mice and also significantly reduced the levels of inflammatory cytokines in inhibitor-treated infected animals. Over the recent years, the understanding of phagocytic mechanisms involving F. tularensis uptake has increased, providing important comparisons with other intracellular pathogens such as Mycobacterium tuberculosis and Listeria monocytogenes (Allen & Aderem, 1996; Aderem & Underhill, 1999) . Several host cell receptors have been targeted to alter the uptake of intracellular pathogens. Of key interest has been the MR (Ezekowitz et al., 1990; Taylor et al., 1990) . Pertinently, the importance of MR has been demonstrated in models of F. tularensis infection (Schulert & Allen, 2006) , where it was shown that monocyte-derived macrophages were significantly more efficient at bacterial uptake than J774A.1 cells and that uptake could be enhanced via induction of the MR. In our in vitro studies, we did not achieve 4 20% inhibition of F. tularensis uptake in J774A.1 and MH-S cells following the addition of mannan. However, this is perhaps not surprising because the assay did not use opsonized bacteria or an MR-positive cell line such as J774-E cells and, importantly, we did not pretreat the cells with mannan before infection. Similarly, the scavenger receptor inhibitors, fucoidan and poly I, which had previously been shown to have an effect on F. tularensis (Pierini, 2006) , did not show 4 20% inhibition in at least one of our in vitro cell culture infection models. Again, this may reflect differences in the methodologies.
Conversely, several other published studies have added validity to the data generated here. The PI-3 kinase inhibitors, wortmannin and LY294002, have been studied extensively for their ability to alter uptake of bacteria including LVS. A lung epithelial cell line, TC-1, has recently been shown to be easily infected by LVS, and the addition of wortmannin caused a decrease in the amount of internalized bacteria . Similarly, Tamilselvam & Daefler (2008) showed that the pretreatment of J774A.1 murine macrophages with wortmannin reduced LVS uptake. In the same study, nocoadazole, cytochalasin-D and genistein were assessed and were shown to have similar or greater ability in decreasing the uptake of LVS in J774A.1 cells, in correlation with our data. In our studies, wortmannin proved to be the most efficient at reducing bacterial uptake. The differences found in our study could reflect the different concentrations used. Furthermore, nocoadazole, cytochalasin-D and genistein were more cytotoxic in our studies and were consequently not selected for further study. In similar infection studies, wortmannin and/or LY294002 altered the uptake or the intracellular replication of Burkholderia cenocepacia and Yersinia enterocolitica (Schulte et al., 1998; Sajjan et al., 2006) . Additionally, Schulert & Allen (2006) reported the importance of the CR3 in models of F. tularensis uptake. We report similar findings with a CR3 inhibitor compound, XVA143, which significantly reduced bacterial uptake in J774A.1 cells and the alveolar MH-S cell line.
Several potential phagocytic inhibitor compounds that were previously unreported, to our knowledge, for inhibiting F. tularensis infection were assessed in this study. These included a broad-spectrum inhibitor of protein kinases, staurosporine, and a phospolipase C inhibitor, PI-PLC, previously shown to inhibit infection with Yersinia pseudotuberculosis and L. monocytogenes, respectively (Rosenshine et al., 1992; Wadsworth & Goldfine, 1999) . None of these compounds were found to be effective at inhibiting the uptake of LVS into the macrophage cell lines. Nevertheless, several compounds tested showed 4 20% inhibition of LVS uptake in at least one of our in vitro cell culture models. Of these, four compounds were analysed further (wortmannin, LY294002, MG132 and XVA143), all of which achieved high levels of inhibition in vitro with little or no measurable cytotoxicity.
Francisella tularensis is capable of infecting several different cell types (Anthony et al., 1991; Ben Nasr et al., 2006) including macrophages (Fortier et al., 1994) . Of particular interest for F. tularensis infection are the cell types in the lung that may come into contact with the bacteria if the host is infected by the aerosol route. Recently, Hall et al. (2008) infected mice with green fluorescent protein-labelled Francisella strains of varying virulence and developed a flow cytometric assay to determine the number and types of infected lung cells. Their data showed that the lung cell composition changed postinfection and that the strain of Francisella also altered the time of infection and the type of cell infected. On day 1 postinfection, it was the alveolar macrophage that was the primary infected cell type, but, by day 3, the neutrophil was the primary infected cell type. In this study, we have developed a lung homogenate infection assay to determine the uptake of bacteria into different lung cell types. A FITC-labelled antibody to LVS was used to measure which specific lung cell types associated with the bacteria. Using flow cytometric techniques similar to those used by Hall and colleagues, we found that alveolar macrophages are the primary phagocytic cell type infected within the lung homogenate, consistent with early infection profiles seen by Hall and colleagues. Not surprisingly, therefore, it was this cell type in which the greatest reduction in bacterial uptake was observed following the addition of all four inhibitor compounds. Additionally, the administration of the compounds caused a reduction in LVS infection in other pulmonary macrophages. As with most in vitro experiments, this assay does have its limitations. For example, the assay does not accurately reflect the changes in lung cell composition over time after infection with F. tularensis. However, this lung homogenate assay may act as a very useful tool for studying the uptake of bacteria during early infection and to determine the effects that compounds may have on specific cell types that phagocytose bacteria.
In this study, we sought to go further than identifying compounds that could alter the uptake of F. tularensis in vitro. We have also analysed the effect of inhibitor treatment on cytokine response and host survival following LVS infection. Previous studies have shown that resistance against F. tularensis, as with most intracellular bacterial pathogens, is dependent on the generation of a type 1 cytokine response via the production of IFN-g, IL-12 and TNF-a, with the early production of these cytokines being crucial in protecting the host (Anthony et al., 1989; Stenmark et al., 1999; Elkins et al., 2002) . Human monocytederived macrophages have been reported to secrete high levels of MCP-1 (CCL2) and TNF-a following infection with LVS (Bolger et al., 2005) . Yet, there is little knowledge regarding the effect of phagocytic inhibition on host response to LVS infection. Here, we have shown that infection of lung cells by LVS causes a significant increase in the secreted levels of IL-6, MCP-1 and TNF-a and that the addition of the inhibitor compounds causes a significant reduction in the secreted levels of these inflammatory cytokines. Furthermore, wortmannin, delivered via the intraperitoneal or the intranasal route to LVS-infected mice, was found to cause altered bacterial uptake into the lung cells and a decreased inflammatory cytokine response. Thus, these results correlated with the in vitro cell data and ex vivo lung data generated in our study. However, a recent study by Medina et al. (2010) has shown that wortmannin-treated bone marrow-derived mouse macrophages produce increased concentrations of TNF-a and IL-6 when infected with LVS. Although these findings are in contrast to the results presented here, there are major differences in the experimental design. These include the use of a different cell type (bone marrow-derived macrophages vs. whole lung cell populations), different mouse strain (C57BL/6 vs. Balb/c) and different time of wortmannin administration (pretreatment vs. time of infection). The dose of wortmannin is likely to be another key factor between experiments. Our studies used a higher concentration of wortmannin at which wortmannin may lose it specificity and act upon other cell functions that could have an effect on cytokine production/ secretion. Indeed, this needs to be considered when analysing all results where these types of compounds are used. As reported, in our studies, wortmannin significantly altered the recruitment of phagocytes into the organs of interest. This alone could account for the changes observed in the inflammatory response, independent of the effect that changes in bacterial uptake may cause. Compounds such as wortmannin have been reported not only to affect phagocytosis but also to affect mitogen-activated kinases and therefore the toll-like receptor signalling pathway, which has a direct response on cytokine production (Ferby et al., 1996) . Nevertheless, the data from our infection models suggested that wortmannin has the potential for therapeutic efficacy by reducing bacterial uptake, enabling host natural defences to be more effective, and causing a reduction in inflammatory cytokines, which may reduce the life-threatening immunopathology associated with many infections. However, in our study, wortmannin treatment of LVS infection did not change the outcome of infection, with no increase in the survival time between wortmannin-treated and nontreated animals. The reason for this lack of protective effect is unclear, although it is possible that the increased extracellular bacteria may enhance systemic infection. Indeed, data suggest that following wortmannin treatment, the blood contained more bacteria than in untreated controls. Furthermore, altered cellular recruitment in mice treated with wortmannin would undoubtedly affect the host response to infection. These changes will have to be further characterized in vivo to fully understand the potential antiinflammatory properties of this compound and the overall therapeutic strategy. In conclusion, this study has shown that several compounds can inhibit the uptake of LVS into a variety of cell types of the lung and cause a decreased 
